{"id":"NCT00857285","sponsor":"Daiichi Sankyo","briefTitle":"Olmesartan Medoxomil Versus Losartan in Patients With Hypertension","officialTitle":"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker \"Olmesartan Medoxomil\" Versus \"Losartan\" in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-05","primaryCompletion":"2003-08","completion":"2003-09","firstPosted":"2009-03-06","resultsPosted":"2009-07-23","lastUpdate":"2009-07-23"},"enrollment":130,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Essential Hypertension"],"interventions":[{"type":"DRUG","name":"olmesartan medoxomil","otherNames":[]},{"type":"DRUG","name":"losartan potassium","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine the efficacy and safety of oral administration of olmesartan medoxomil compared to losartan in subjects with mild to moderate hypertension.","primaryOutcome":{"measure":"Mean Change of Sitting dBP From Baseline to Week 12","timeFrame":"Baseline to 12 weeks","effectByArm":[{"arm":"Olmesartan Medoxomil","deltaMin":-14.8,"sd":12.5},{"arm":"Losartan Potassium","deltaMin":-11.6,"sd":9.46}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":3,"countries":["Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}